Abstract
1 Nine patients with rheumatoid arthritis or non-inflammatory backache were given soluble aspirin (65 mg/kg body weight) daily. There was no significant difference between the plasma salicylate of those with rheumatoid arthritis and those with backache. 2 Two patients had plasma salicylate values that differed significantly from the remainder but neither these results nor the marginal differences between plasma salicylate levels of the others could be explained by individual variations in the capacity for excreting salicyluric acid or salicyl phenolic glucuronide. 3 Increasing the dose of aspirin in four patients demonstrated the reduced proportions of salicyluric acid and salicyl phenolic glucuronide excreted at high doses and the increased importance of unchanged salicylic acid as an excretory pathway. These findings are consistent with a limiting capacity for salicyluric acid and salicyl phenolic glucuronide synthesis and excretion. 4 The findings in one patient suggested that inter-subject variations in the capacity for producing salicyl phenolic glucuronide and salicyluric acid may have an effect on plasma salicylate levels at high doses of aspirin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boardman P. L., Hart F. D. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J. 1967 Nov 4;4(5574):264–268. doi: 10.1136/bmj.4.5574.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- CUMMINGS A. J., MARTIN B. K. FACTORS INFLUENCING THE PLASMA SALICYLATE CONCENTRATION AND URINARY SALICYLATE EXCRETION AFTER ORAL DOSAGE WITH ASPIRIN. Biochem Pharmacol. 1964 May;13:767–776. doi: 10.1016/0006-2952(64)90013-9. [DOI] [PubMed] [Google Scholar]
- Cid E., Delporte J. P., Jaminet F. Méthode rapide de dosage des salicylates dans le sang. Pharm Acta Helv. 1971 Dec;46(12):737–741. [PubMed] [Google Scholar]
- Hollister L., Levy G. Some aspects of salicylate distribution and metabolism in man. J Pharm Sci. 1965 Aug;54(8):1126–1129. doi: 10.1002/jps.2600540806. [DOI] [PubMed] [Google Scholar]
- Levy G., Tsuchiya T., Amsel L. P. Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther. 1972 Mar-Apr;13(2):258–268. doi: 10.1002/cpt1972132258. [DOI] [PubMed] [Google Scholar]
- Levy G., Tsuchiya T. Salicylate accumulation kinetics in man. N Engl J Med. 1972 Aug 31;287(9):430–432. doi: 10.1056/NEJM197208312870903. [DOI] [PubMed] [Google Scholar]
- Paulus H. E., Siegel M., Mongan E., Okun R., Calabro J. J. Variations of serum concentrations and half-life of salicylate in patients with rheumatoid arthritis. Arthritis Rheum. 1971 Jul-Aug;14(4):527–532. doi: 10.1002/art.1780140412. [DOI] [PubMed] [Google Scholar]
- REYNOLDS R. C., CLUFF L. E. Interaction of serum and sodium salicylate: changes during acute infection and its influence on pharmacological activity. Bull Johns Hopkins Hosp. 1960 Nov;107:278–290. [PubMed] [Google Scholar]
- SCHACHTER D., MANIS J. G. Salicylate and salicyl conjugates: fluorimetric estimation, biosynthesis and renal excretion in man. J Clin Invest. 1958 Jun;37(6):800–807. doi: 10.1172/JCI103667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SCHACHTER D. The chemical estimation of acyl glucuronides and its application to studies on the metabolism of benzoate and salicylate in man. J Clin Invest. 1957 Feb;36(2):297–302. doi: 10.1172/JCI103424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- The clinical pharmacology of salicylates. Calif Med. 1969 May;110(5):410–422. [PMC free article] [PubMed] [Google Scholar]
- Wagner J. G. Fallacy in concluding there are zero-order kinetics from blood level and urinary excretion data. J Pharm Sci. 1967 May;56(5):586–594. doi: 10.1002/jps.2600560509. [DOI] [PubMed] [Google Scholar]